Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.49 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.49 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.49 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.49 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.45 |
| ▸ | P2RY2 | P41231 | 9/20 | 0.41 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.41 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4078262 | 1.00 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL2766878 | 1.00 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL14929468 | 1.00 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL13722079 | 1.00 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL13978164 | 1.00 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL2157170 | 1.00 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL2511160 | 1.00 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL2157176 | 1.00 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL13976549 | 1.00 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL1097185 | 1.00 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7034133-B2 | Locked Nucleoside Analogues is a biochemical conjugate of nucleotides; as an aptamer in specific binding of antibiotics, drugs, amino acids, peptides, enzymes, saccharides, polysaccharides; heat resistance | EXIQON A/S (DK) | 2006-04-25 | — | — | US | claimed |
| EP-1178999-B1 | L-RIBO-LNA ANALOGUES | SANTARIS PHARMA AS (DK) | 2007-03-14 | — | — | EP | disclosed |
| US-7053207-B2 | L-ribo-LNA analogues | EXIQON A/S (DK) | 2006-05-30 | — | — | US | disclosed |
| US-20030087230-A1 | L-Ribo-LNA analogues | SANTARIS PHARMA A/S (DK) | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087230-A1 | L-Ribo-LNA analogues | RNGTT, NCL, RNASEL | SLC28A1 188/4885SLC28A2 152/4885SLC29A1 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.